Rituximab + Gemcitabine
Phase 2Terminated 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, B-Cell
Conditions
Lymphoma, B-Cell
Trial Timeline
Apr 1, 2005 → Mar 1, 2007
NCT ID
NCT00216164About Rituximab + Gemcitabine
Rituximab + Gemcitabine is a phase 2 stage product being developed by Eli Lilly for Lymphoma, B-Cell. The current trial status is terminated. This product is registered under clinical trial identifier NCT00216164. Target conditions include Lymphoma, B-Cell.
What happened to similar drugs?
18 of 20 similar drugs in Lymphoma, B-Cell were approved
Approved (18) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00216164 | Phase 2 | Terminated |
Competing Products
20 competing products in Lymphoma, B-Cell